LLY

$989.12

Market ClosedAs of Mar 16, 8:02 PM UTC

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$989.12
Potential Downside
11.3%
Whystock Fair Value$877.42
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDrug Manufacturers - General

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humal...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$885.28B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
43.10
Beta
Defensive asset. Lower volatility than the S&P 500.
0.43
Div Yield
Strong income play. Yield provides a meaningful total return floor.
63.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
101.16%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.78

Recent News

Insider Monkey
Mar 16, 2026

Wall Street Firms Turn Bullish on Eli Lilly and Company (LLY) Buoyed by GLP-1 Medication Expansion Plans

Eli Lilly and Company (NYSE:LLY) is one of Goldman Sachs top healthcare stocks. On March 10, analysts at Bernstein SocGen reiterated an Outperform rating on Eli Lilly (NYSE:LLY) with a $1,300 price target. The positive stance comes on the heels of the company launching the Employer Connect platform to enhance access to its obesity medications […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Investor's Business Daily
Mar 16, 2026

Structure Therapeutics Pops; But Can It Take On Lilly's Looming Obesity Pill?

Structure Therapeutics shares surged Monday after the biotech said its daily pill helped patients lose up to 39 pounds over a 44-week study.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Motley Fool
Mar 16, 2026

Is There Too Much Bullishness Priced Into Eli Lilly's Stock Price?

Eli Lilly's stock is down this year, and its high valuation may be a big reason why.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Simply Wall St.
Mar 16, 2026

Eli Lilly Pediatric EBGLYSS Data Strengthens Broader Immunology Growth Story

Eli Lilly (NYSE:LLY) reported positive topline Phase 3 results for EBGLYSS (lebrikizumab) in pediatric patients with moderate to severe atopic dermatitis. The data support a potential label expansion into pediatric use, further building out Lilly's immunology and dermatology presence. This update extends the EBGLYSS story beyond adult indications and arrives as the company continues to invest in its broader pipeline. Eli Lilly, trading at around $985.08, has already delivered very large...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Barrons.com
Mar 16, 2026

A New GLP-1 Pill Melted Away the Pounds. Is Structure Therapeutics a Takeover Candidate?

Structure Therapeutics said its GLP-1 pill helped patients lose more than 16% of their body weight in a midstage trial, outperforming results reported for competing obesity drugs.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
LLY Stock Analysis & Real-Time Data | Whystock